The Role of Mucosal Associated Invariant t Lymphocytes in Breast Cancer

NCT07000396 | Not Yet Recruiting DMC

• 1 other identifier: MAIT Cells in Breast Cancer
• Study Type: observational
• Target: 74
• Locations: 0 countries
• Sites: N/A

Brief Summary

Evaluation of MAIT cells in patient recently diagnosed as cancer breast and its correlation with clinical outcome. Mucosal Associated Invariant T cells are a population of unconventional T cells which are enriched in mucosal tissues such as the lung and gut but are also present in other tissues including the skin, adipose tissue and the liver \[4,5,6,7\]. Unlike conventional T cells, MAIT cells are not restricted by MHC but recognize the MHC-related protein MR1. MAIT cells express a semi-invariant TCR α-chain (Vα7.2-Jα33/20/12 in humans) and a limited repository of TCR-β chains, mostly from the TRBV20 and TRBV6 gene families \[8,9\] MAIT cells can also be activated independent of TCR engagement, via pro-inflammatory cytokines such as IL-18 \[10,11,12\]. Upon activation, MAIT cells can rapidly respond, producing a milieu of cytokines including interferon-gamma , tumor necrosis factor alpha and interleukin-17 \[11,14\]. MAIT cell cytokine profiles can vary depending on their tissue localization \[15\]. Peripheral MAIT cells are potent producers of IFNγ and TNFα, whereas IL-17 producing MAIT cells are rare in the periphery but are more abundant in, for example, the female genital mucosa \[16\]. In addition to cytokine production, A central role in immune protection against cancer is played by T lymphocytes, particularly CD8+ T cells .Their infiltration in tumor cell nests is usually associated with a favorable prognosis and may predict outcome of therapies with drugs that block immune inhibitory receptors (checkpoint blockade. A recent meta-analysis reported that tumor-infiltrating CD8+ lymphocytes can be identified in 48% of all breast cancers .Interestingly, triple-negative breast cancers show the highest incidence of lymphocyte predominance. Moreover, TILs were found to be prognostic in triple-negative breast cancer, and higher levels of TILs were predictive for trastuzumab benefit in HER2+ disease. These findings suggest that therapies that enforce immune responses could potentially improve patient survival.

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Correlation between mucosal associated invariant t lymphocytes and breast cancer outcome

  The role of mucosal associated invariant t lymphocytes in breast cancer

  Baseline

Study Arms (2)

Group A

breast cancer patients

Group B

normal individual (control)

Eligibility Criteria

• Age: 18 Years - 75 Years
• Gender Eligibility Details: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Female patients admitted at South Egypt cancer institute who diagnosed as breast cancer based on full clinical, radiologic and pathologic assays

You may qualify if:

• Female patients admitted at South Egypt cancer institute who diagnosed as breast cancer based on full clinical, radiologic and pathologic assays

You may not qualify if:

• Patients receive any anti-cancer therapy.
• Patients diagnosed with other concomitante cancer or chronic disease

Sponsors & Collaborators

• Assiut University: lead

Related Publications (1)

• Zumwalde NA, Haag JD, Gould MN, Gumperz JE. Mucosal associated invariant T cells from human breast ducts mediate a Th17-skewed response to bacterially exposed breast carcinoma cells. Breast Cancer Res. 2018 Sep 12;20(1):111. doi: 10.1186/s13058-018-1036-5.

  PMID: 30208917 BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: May 24, 2025
• First Posted: June 2, 2025
• Study Start: December 1, 2025
• Primary Completion: August 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: July 30, 2025

Record last verified: 2025-05